GenoMed Offers Only Published West Nile Treatment Free Of Charge

Main Category: Infectious Diseases / Bacteria / Viruses
Article Date: 12 Sep 2008 - 5:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today, as the WNV season reaches its peak, that it still has the only effective treatment against West Nile virus encephalitis published in the medical literature.

GenoMed first filed a patent for using a common class of blood pressure pills against most viruses during the SARS epidemic in 2003. The patent is pending. A pending patent has the same legal standing as a granted patent, meaning that license fees can be charged.

Nevertheless, GenoMed is offering its treatment for West Nile virus free of charge, in keeping with its mission to improve public health.

GenoMed's first 8 WNV patients were published in July, 2004. Since then, GenoMed has had 80% success in human patients (23 of 29) as well as horses (8 of 10), and 50% (6 of 12) in birds.

Said David Moskowitz MD, GenoMed's CEO and Chief Medical Officer, "Today is a very sad day for our country. GenoMed would like to do its part to make people feel just a little bit better."

About GenoMed

GenoMed, a genomics-based Disease Management company in St. Louis, has had encouraging results treating West Nile virus encephalitis since 2003. The earlier the treatment is begun, the better the outcome, so public education is key. Anybody who wants to download GenoMed's WNV trial protocol can do so for free at any time by clicking on the "West Nile trial" link on GenoMed's homepage at http://www.genomed.com.

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

GenoMed